PUBLISHER: The Business Research Company | PRODUCT CODE: 1704451
PUBLISHER: The Business Research Company | PRODUCT CODE: 1704451
Genital herpes is a sexually transmitted infection (STI) caused primarily by the herpes simplex virus type 2 (HSV-2) or, less commonly, by the herpes simplex virus type 1 (HSV-1). It typically appears as sores or blisters on the genital area, buttocks, or anal region. Transmission occurs through sexual contact with an infected person. Antiviral medications are used to manage symptoms and reduce the risk of transmission to sexual partners.
The diagnosis and treatment of genital herpes involve identifying the infection in patients through methods such as physical examinations, laboratory tests, and reviewing patient history. Treatment methods include oral, injectable, and topical medications, distributed through hospital pharmacies, retail pharmacies, and other channels.
The genital herpes market research report is one of a series of new reports from the business research company that provides genital herpes market statistics, including genital herpes industry global market size, regional shares, competitors with an genital herpes market share, detailed genital herpes market segments, market trends and opportunities, and any further data you may need to thrive in the genital herpes industry. This genital herpes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The genital herpes market size has grown strongly in recent years. It will grow from $2.19 billion in 2024 to $2.34 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to increasing awareness and diagnosis, increasing advancements in treatment, improved access to healthcare, public health campaigns, and socio-demographic factors.
The genital herpes market size is expected to see strong growth in the next few years. It will grow to $3.05 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to growing awareness and education, advancements in treatment and vaccines, increasing incidence rates, digital health technologies, expanding healthcare access, and rising STI awareness programs. Major trends in the forecast period include the adoption of telemedicine, advancements in antiviral therapies, research and development in vaccines, expansion of healthcare access, enhanced public awareness campaigns, and the integration of AI and data analytics.
The genital herpes market is poised for growth, driven by increasing attention to sexual health. This focus reflects a growing understanding of its pivotal role in overall well-being and life quality. Sexual health services for genital herpes encompass diagnosis, treatment, counseling, and ongoing management. These services support individuals in managing outbreaks, preventing transmission, and addressing emotional and relationship challenges linked to the condition. Notably, the Local Government Association reported a 33% surge in sexual health consultations in 2022, totaling 4.5 million, along with a 13% increase in diagnostic tests, totaling 2.2 million compared to 2021. Thus, the heightened emphasis on sexual health is expected to boost the genital herpes market.
Major companies in the genital herpes market, are embracing strategic partnerships to bolster their technological capabilities and market presence. These partnerships involve collaborative efforts between organizations to combine resources and expertise toward shared objectives. For instance, in June 2022, Eurocine Vaccines AB entered into a research and collaboration agreement with Redbiotec AG. This partnership grants Eurocine Vaccines exclusive global rights for developing, manufacturing, and commercializing vaccine candidates targeting Herpes Simplex Virus Type 2 (HSV-2), utilizing mRNA- and protein-based technologies. Eurocine Vaccines will manage and finance all activities related to development, manufacturing, and commercialization until a subsequent out-licensing agreement with a third party is secured.
In July 2022, Flerie Invest AB, a Sweden-based investment company specializing in the pharmaceuticals and healthcare sectors, acquired a 15% stake in Eurocine Vaccines AB for an undisclosed sum. This investment is aimed at accelerating the development of medical innovations that address critical patient needs. Flerie Invest intends to support the advancement of Eurocine Vaccines' pipeline of products under development, consistent with its strategy of investing in the biotechnology and life sciences industries. Eurocine Vaccines AB, headquartered in Sweden, focuses on developing therapies and products for the treatment of genital herpes disease.
Major companies operating in the genital herpes market are Pfizer Inc, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, BioNTech SE, Viatris Inc, Teva Pharmaceuticals Inc, Sandoz Inc, Fresenius Kabi AG, Valeant Pharmaceuticals International Inc, Sun Pharmaceutical Industries Ltd, Bausch + Lomb Corporation, Dr Reddy's Laboratories Ltd, Apotex Inc, Zydus Group, Genocea Biosciences Inc, Glenmark Pharmaceuticals Inc, Maruho Co Ltd, Romark Laboratories, Eurocine Vaccines AB, Vical Incorporated
North America was the largest region in the genital herpes market in 2024. The regions covered in the genital herpes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the genital herpes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The genital herpes market consists of revenues earned by entities by providing services such as diagnostic testing, patient education, counseling, and management of symptoms and outbreaks. The market value includes the value of related goods sold by the service provider or included within the service offering. The genital herpes market also includes sales of antiviral medications, topical treatments, diagnostic test kits, and preventive products such as vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Genital Herpes Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on genital herpes market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for genital herpes ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The genital herpes market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.